← Eichor
Study identifier: NCT07091526 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Whether Control of Serum Uric Acid (SUA) Improves Survival After Pancreatic Cancer

Condition: Serum Uric Acid  ·  Sponsor: Hepatopancreatobiliary Surgery Institute of Gansu Province

PhaseN/A
Planned participants168
Who can joinAll sexes, 18 Years to 85 Years
Healthy volunteersNo

About this study

This retrospective study aims to analyze the impact of postoperative changes in serum uric acid (SUA) levels on the prognosis of patients undergoing pancreatic cancer resection.

This description comes directly from the study's public registry record.

Talk to the study team

Wenbo Meng, M.D. Ph. D.  ·  13919177177  ·  mengwb@163.com

Zhengping An, M.D.  ·  18298415512  ·  anzhp2023@lzu.edu.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Hepatopancreatobiliary Surgery Institute of Gansu ProvinceLanzhou, Gansu, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07091526